Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme

Inclusion Criteria

• •The pathological result of glioblastoma WHO grade 4;
• •Received standard TMZ chemotherapy and radiotherapy;
• •It is not suitable to undergo surgical resection of the lesion again or other drug treatment, or the patient refuses other treatment;
• •Men and women aged 18-75;
• •Disease progression was confirmed by CT or MRI examination within 4 weeks before enrollment;
• •KPS score ≥70;
• •Expected survival time ≥ 3 months, and can meet the follow-up requirements;
• •Within 7 days before the start of treatment, the results of routine blood tests, liver and renal function tests, and hemagglutination laboratory tests meet the following criteria:
• •Leukocyte (WBC) ≥ 3.0×109/L
• •Platelets (PLT) ≥ 100×109/L
• •Neutrophil (ANC) ≥ 1.5×109/L
• •Hemoglobin (HGB) ≥ 90g/L
• •Serum albumin ≥2.8g/dL
• •Aspartate aminotransferase (AST) ≤2.5× upper limit of normal (ULN) (\< 5×ULN for liver metastases)
• •Alanine aminotransferase (ALT) ≤2.5×ULN (≤5×ULN for liver metastases)
• •Total bilirubin (TIBC) ≤1.5×ULN, patients with liver cancer or liver metastases should ≤2×ULN
• •Serum creatinine (CR)≤1.5×ULN or creatinine clearance ≥50ml/min
• •AST and ALT levels ≤ 2.5×ULN, and patients with liver metastases or liver cancer should ≤ 5×ULN
• •International Normalized ratio (INR) ≤ 1.5
• •Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5×ULN
• •Pregnancy should be ruled out for fertile women, and HCG tests for early pregnancy must be negative; Both male and female participants should ensure that they use contraception during the study and continue to use contraception until the end of the follow-up period;
• •Volunteer to participate in the clinical study, cooperate with the doctor to carry out the study, and sign the informed consent form.